Previous 10 | Next 10 |
2023-06-06 17:21:13 ET Gainers: GeneDx Holdings ( WGS ) +6% . Zumiez ( ZUMZ ) +6% . Stitch Fix ( SFIX ) +6% . LianBio ( LIAN ) +5% . Dave & Buster's Entertainment ( PLAY ) +5% . Losers: Couchbase ( BASE ) -17% ...
SHANGHAI, China and PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced positive topline results from a Phase 2a proof of concept trial eva...
SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the followi...
2023-05-14 14:20:00 ET Summary Bliss Biopharma (Hangzhou) announced it may out-license global rights (ex-China) for its HER2 ADC to Japan’s Eisai Pharma in a deal with a potential value of $2 billion. Shanghai Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to...
2023-05-12 07:01:07 ET LianBio press release ( NASDAQ: LIAN ): Q1 GAAP EPS of -$0.22 beats by $0.05 . Cash, cash equivalents, marketable securities and restricted cash at March 31, 2023 totaled $286.6 million compared to $302.4 million as of December 31, 2022...
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint China National Medical Products Administration ( NMPA) accepted mavacamten New Drug Application (NDA) with priority review Mavacamten commer...
2023-05-11 08:06:38 ET LianBio ( NASDAQ: LIAN ) said Pharmaceutical Administration Bureau of the Macau approved Camzyos (mavacamten) to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the Macau Special Administrative Region (SAR) of China "...
SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that CAMZYOS ® (mavacamten) has received marketing app...
2023-04-26 10:09:11 ET Gainers: Scilex Holding ( SCLX ) +14% . Cytek Biosciences ( CTKB ) +12% . Minerva Neurosciences ( NERV ) +10% . Vincerx Pharma ( VINC ) +9% . LianBio ( LIAN ) +7% . Losers: ZyVersa Therapeutics ( Z...
2023-04-26 08:53:02 ET Bristol Myers Squibb ( NYSE: BMY ) and LianBio's ( NASDAQ: LIAN ) drug Camzyos (mavacamten) met the main goal of a phase 3 trial in Chinese patients with a type of heart disease. LianBio was evaluating mavacamten in the study, dubbed EXPLORE...
News, Short Squeeze, Breakout and More Instantly...
LianBio Company Name:
LIAN Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 211.4% to $0.4422 on volume of 532,901,553 shares Fisker Inc. Class A (FSR) rose 12.8% to $0.1747 on volume of 376,460,729 shares Better Therapeutics Inc. (BTTX) rose 27.4% to $0.0446 on volume...
A look at the top 10 most actives in the United States Grab Holdings Limited (GRAB) fell 0.2% to $3.235 on volume of 103,635,000 shares Better Therapeutics Inc. (BTTX) rose 108.6% to $0.073 on volume of 98,804,254 shares Verb Technology Company Inc. (VERB) rose 156.3% to $0.3639 on volume...
SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) (“LianBio” or the “Company”), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it ha...